Dr Tanmoy Kumar Mandal

Dr. Tanmoy Kumar Mandal is a Consultant in the Department of Medical Oncology at Manipal Hospitals, Mukundapur, Kolkata. He has over a decade of experience in diagnosing and treating solid tumours and haematological malignancies. His clinical practice includes the use of chemotherapy, immunotherapy, targeted therapy, and hormone therapy for cancer management. He is involved in research activities and academic contributions related to oncology. He communicates with patients in English, Bengali, and Hindi.

Educational Qualifications

• MBBS – NRS Medical College, Kolkata
• DTCD – Diploma in Tuberculosis and Chest Diseases
• MD (General Medicine) – Calcutta National Medical College, Kolkata
• DM (Medical Oncology) – Tata Memorial Hospital, Mumbai
• DNB (Medical Oncology)

Professional Experience

• Consultant – Medical Oncology, Manipal Hospitals, Mukundapur, Kolkata

Awards & Achievements

• Real-world eligibility for treatment-free remission in chronic myeloid leukaemia patients – International CML Conference 2017
• Long-term and short-term outcomes in chronic myeloid leukaemia treated with generic and innovator imatinib – International CML Conference 2017
• Outcomes of chronic myeloid leukaemia–chronic phase patients treated with generic imatinib – Mumbai Hematology Group Annual Meeting, March 2018
• Trastuzumab Emtansine in HER2-positive metastatic breast cancer – ASCO E-poster, 2018
• Chemotherapy-induced anaemia (Desidustat, Zydus Cadila) – Phase 1 Clinical Trial, Principal Investigator, 2021
• Non-small cell lung carcinoma (Dacomitinib, Pfizer / ICON PLC) – Phase 4 Clinical Trial, Principal Investigator, 2021 – Ongoing
• Breast / Ovarian / Prostate cancer (Olaparib, NATCO Pharma / CBCC Global) – BA/BE Study, Principal Investigator, 2021 – Ongoing
• Prostate cancer (Talazoparib, Pfizer / ICON PLC) – Phase 3 Clinical Trial, Principal Investigator, 2021
• Renal cell carcinoma (Sunitinib, Axis Clinicals) – BA/BE Study, Principal Investigator, 2021 – Ongoing
• Relapsed multiple myeloma (Carfilzomib, Amgen) – Phase 4 Clinical Trial, Principal Investigator, 2021 – Ongoing
• SPEAR Registry (PIK3CA testing, Novartis) – Observational Study, Principal Investigator, 2021 – Ongoing

Professional Memberships

• European Society of Medical Oncologists (ESMO)
• Indian Society of Medical and Paediatric Oncologists (ISMPO)
• American Society of Clinical Oncologists (ASCO)
• Immune-Oncological Society of India (IOSI)

Certifications

• MRCP (Medical Oncology – Specialty Certificate Examination)
• ESMO Certification (2019)

Publications

• RMAC study on metronomic adjuvant chemotherapy in recurrent head and neck cancers – Oral Oncology, 2022
• Osteosarcoma journey over two decades in India – Pediatric Blood Cancer, 2019
• Influence of hypothyroidism post chemoradiation on outcomes in head and neck cancer – Journal of Clinical Oncology, 2018
• Demography and pattern of care of patients with head-and-neck carcinoma – Cancer Research Statistics and Treatment
• Outcomes of splenic marginal zone lymphoma treated with rituximab or splenectomy – Clinical Lymphoma, Myeloma & Leukemia
• Additional peer-reviewed publications exactly as listed on the hospital page